Ronald N. Marcus, MD

Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia

March 24, 2025

Xanomeline and trospium showed improvement in agitation as measured by the PANSS-Excited Component in participants with acute exacerbations of schizophrenia.

Paul P. Yeung, Alan Breier, Haiyuan Zhu, et al

Original Research

A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder

January 15, 2014

Robert D. McQuade, Ronald N. Marcus, James M. Eudicone, et al

Article

Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study

July 26, 2011

Robert D. McQuade, Ronald N. Marcus, Robert L. Findling, et al

Original Research

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

December 17, 2009

Maurizio Fava, Ronald N. Marcus, Madhukar H. Trivedi, et al

Original Research

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

December 31, 2008

Maurizio Fava, Ronald N. Marcus, Madhukar H. Trivedi, et al

Original Research

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

December 15, 2008

Maurizio Fava, Ronald N. Marcus, Madhukar H. Trivedi, et al

Original Research

The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia: A Pooled Post Hoc Analysis From 5 Short-Term Studies

December 2, 2008

Philip G. Janicak, Ira D. Glick, Stephen R. Marder, et al

Original Research

A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine

July 31, 2008

Robert D. McQuade, Ronald N. Marcus, William H. Carson, et al

Letter to the Editor

Reply to Aripiprazole and Perphenazine: No Difference

November 15, 2007

Robert D. McQuade, Ronald N. Marcus, Raymond Sanchez, et al

Original Research

Comparison of Metabolic Syndrome Incidence Among Schizophrenia Patients Treated With Aripiprazole Versus Olanzapine or Placebo

October 15, 2007

Ronald N. Marcus, William H. Carson, Daniel E. Casey, et al

Original Research

Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo

October 15, 2007

Robert D. McQuade, Ronald N. Marcus, James M. Eudicone, et al

Original Research

Antimanic Response to Aripiprazole in Bipolar I Disorder Patients Is Independent of the Agitation Level at Baseline

September 17, 2007

David T. Crandall, Robert D. McQuade, Ronald N. Marcus, et al

Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia

A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder

Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia: A Pooled Post Hoc Analysis From 5 Short-Term Studies

A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine

Reply to Aripiprazole and Perphenazine: No Difference

Comparison of Metabolic Syndrome Incidence Among Schizophrenia Patients Treated With Aripiprazole Versus Olanzapine or Placebo

Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo

Antimanic Response to Aripiprazole in Bipolar I Disorder Patients Is Independent of the Agitation Level at Baseline

ELSEWHERE:

FOLLOW US:

Ronald N. Marcus, MD

Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia

A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder

Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia: A Pooled Post Hoc Analysis From 5 Short-Term Studies

A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine

Reply to Aripiprazole and Perphenazine: No Difference

Comparison of Metabolic Syndrome Incidence Among Schizophrenia Patients Treated With Aripiprazole Versus Olanzapine or Placebo

Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo

Antimanic Response to Aripiprazole in Bipolar I Disorder Patients Is Independent of the Agitation Level at Baseline

Insightful. Evidence-based. Human-centered.

Subscribe to readmore articles

Subscribe to read
more articles